← Leaderboards
Gerald S Lipshutz
University Of California Los Angeles
$7,859,338
Attributed
$8,115,701
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2007–23$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,115,701 · 10
By mechanism
R01$5,064,209 · 3
R21$852,500 · 2
R61$818,416 · 1
K08$557,850 · 1
R56$512,726 · 1
R03$310,000 · 2
Top collaborators
- Alice F Tarantal1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Harvey R. Herschman$16,718,124
- Lily Wu$3,586,954
- Stephen D Cederbaum$1,561,049
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyLifeCellsBaseAdeno-Associated Viral VectorMouse ModelNeonatalKnockout MiceHyperargininemiaHyperammonemiaEnzymesRecombinantsImpairmentUrea CycleViral VectorGenesHepaticLiverNervous System TraumaPsyche StructureAnimalsImmune ResponseGene ExpressionArginase
Grant awards (31)
Gene Therapy Clinical Candidate Development for Carbamoyl Phosphate Synthetase Deficiency$429,201
R61 · FY2023 · NS · contact PI
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency$341,250
R01 · FY2023 · NS · contact PI
Gene Therapy Clinical Candidate Development for Carbamoyl Phosphate Synthetase Deficiency$389,215
R61 · FY2022 · NS · contact PI
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency$341,250
R01 · FY2022 · NS · contact PI
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency$341,250
R01 · FY2021 · NS · contact PI
Cell and Gene Replacement Strategies for Arginase Deficiency$328,664
R01 · FY2021 · NS · contact PI
A pluripotent stem cell platform for exploring the cause and mechanism of neuronal dysfunction in arginase deficiency$429,000
R21 · FY2020 · NS · contact PI
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency$341,250
R01 · FY2020 · NS · contact PI
Cell and Gene Replacement Strategies for Arginase Deficiency$328,903
R01 · FY2020 · NS · contact PI
Elucidation of the Role of the Arginase Isoforms in Normal Neuronal Development and Function$156,000
R03 · FY2020 · NS · contact PI
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency$341,250
R01 · FY2019 · NS · contact PI
Cell and Gene Replacement Strategies for Arginase Deficiency$329,464
R01 · FY2019 · NS · contact PI
Cell and Gene Replacement Strategies for Arginase Deficiency$329,579
R01 · FY2018 · NS · contact PI
Investigation of Neuroanatomical Alterations in Arginase Deficiency After Neonatal Gene Therapy$77,000
R03 · FY2018 · NS · contact PI
Cell and Gene Replacement Strategies for Arginase Deficiency$341,502
R01 · FY2017 · NS · contact PI
Investigation of Neuroanatomical Alterations in Arginase Deficiency After Neonatal Gene Therapy$77,000
R03 · FY2017 · NS · contact PI
Development of Molecular Therapy for Carbamoyl Phosphate Synthetase Deficiency$231,000
R21 · FY2016 · NS · contact PI
Development of Molecular Therapy for Carbamoyl Phosphate Synthetase Deficiency$192,500
R21 · FY2015 · NS · contact PI
Immunologic Aspects of In Utero or Neonatal AAV-Based Gene Therapy$512,726
R56 · FY2014 · AI · contact PI
Pathophysiology and Gene Replacement Strategies for Arginase Deficiency$326,836
R01 · FY2014 · NS · contact PI
Pathophysiology and Gene Replacement Strategies for Arginase Deficiency$318,583
R01 · FY2013 · NS · contact PI
Pathophysiology and Gene Replacement Strategies for Arginase Deficiency$57,277
R01 · FY2013 · NS · contact PI
Pathophysiology and Gene Replacement Strategies for Arginase Deficiency$330,138
R01 · FY2012 · NS · contact PI
Pathophysiology and Gene Replacement Strategies for Arginase Deficiency$330,138
R01 · FY2011 · NS · contact PI
The Immune Response to Viral Vector and Transgenes in the Fetus$102,600
K08 · FY2011 · HD · contact PI
Pathophysiology and Gene Replacement Strategies for Arginase Deficiency$336,875
R01 · FY2010 · NS · contact PI
The Immune Response to Viral Vector and Transgenes in the Fetus$102,600
K08 · FY2010 · HD · contact PI
The Immune Response to Viral Vector and Transgenes in the Fetus$44,850
K08 · FY2010 · HD · contact PI
The Immune Response to Viral Vector and Transgenes in the Fetus$102,600
K08 · FY2009 · HD · contact PI
The Immune Response to Viral Vector and Transgenes in the Fetus$102,600
K08 · FY2008 · HD · contact PI
The Immune Response to Viral Vector and Transgenes in the Fetus$102,600
K08 · FY2007 · HD · contact PI